1708
G. De Nanteuil et al. / Bioorg. Med. Chem. Lett. 13 (2003) 1705–1708
9. Charlton, P.; Faint, R.; Barnes, C.; Bent, F.; Folkes, A.;
Acknowledgements
Templeton, D.; Mackie, I.; Machin, S.; Bevan, P. Fibrinolysis
Proteolysis 1997, 11, 51.
10. De Nanteuil, G.; Lila, C.; Rupin, A.; Verbeuren, T. J.
16th International Symposium on Medicinal Chemistry,
Bologne, Sept. 18–22, 2000, Abst. PA 112.
The authors wish to thank Daniele Heno and Edith
Bonhomme for their skillful technical assistance.
References and Notes
11. (a) Folkes, A.; Brown, S. D.; Canne, L. E.; Chan, J.;
Engelhardt, E.; Epshteyn, S.; Faint, R.; Golec, J.; Hanel, A.;
Kearney, P.; Leahy, J. W.; Mac, M.; Matthews, D.; Prisbylla,
M. P.; Sanderson, J.; Simon, R. J.; Tesfai, Z.; Vicker, N.;
Wang, S.; Webb, R. R.; Charlton, P. Bioorg. Med. Chem. Lett.
2002, 12, 1063. (b) Wang, S.; Golec, J.; Miller, W.; Miluti-
novic, S.; Folkes, A.; Williams, S.; Brooks, T.; Hardmann, K.;
Charlton, P.; Wren, S.; Spencer, J. Bioorg. Med. Chem. Lett.
2002, 12, 2367.
1. Krishnamurti, C.; Alving, B. M. Semin. Thromb. Haemost.
1992, 18, 67.
2. Egelund, R.; Schousboe, S. L.; Sottrup-Jensen, L.; Roden-
burg, K. W.; Andreasen, P. A. Eur. J. Biochem. 1997, 248, 775.
3. (a) Erikson, L. A.; Fici, G. J.; Lund, J. E.; Boyle, T. P.;
Polites, H. G.; Marotti, K. R. Nature 1990, 346, 74. (b) Car-
meliet, P.; Stassen, J. M.; Schoonjans, L.; Ream, B.; Van den
Oord, J. J.; De Mol, M.; Mulligan, R. C.; Collen, D. J. Clin.
Invest. 1993, 92, 2756.
12. Krubsack, A. J.; Higa, T. Tetrahedron Lett. 1968, 49,
5149.
4. Juhan-Vague, I.; Alessi, M. C. Thrombosis and Haemostasis
1997, 78, 656.
13. Rupin, A.; Belsacq, A.-S.; De Nanteuil, G.; Verbeuren, T.
J. Thromb. Haemost., 1999 (Suppl. Abstr. 1021).
5. Stout, T. J.; Graham, H.; Buckley, D. I.; Matthews, D. J.
Biochemistry 2000, 39, 8460.
14. tPa (0.42 nM) was mixed with plasminogen (800 nM),
fibrinogen (7.5 mg/mL), and human recombinant active PAI-1
(Molecular Innovations, 2 nM) in the presence or not of the
tested compound; thrombin (14 nM) was then added and
absorbance was measured each 10 min for 12 h at 37 ꢀC to
determine lysis times. A calibration curve (lysis times vs active
PAI-1 concentrations) was constructed to calculate the active
PAI-1 concentration inhibited by each compound concen-
tration; the concentration of compound inhibiting 50% of
active PAI-1 (IC50) was then determined.
6. Levi, M.; Biemond, B. J.; Van Zonneveld, A. J.; Ten Cate,
J. W.; Pannekoek, H. Circulation 1995, 91, 1175.
7. Eitzman, D. T.; Fay, W. P.; Lawrence, D. A.; Francis-
Chmura, A. M.; Shore, J. D.; Olson, S. T.; Ginsburg, D.
J. Clin. Invest. 1995, 95, 2416.
8. Bryans, J.; Charlton, P.; Chicarelli-Robinson, I.; Collins,
M.; Faint, R.; Latham, C.; Shaw, I.; Trew, S. J. Antibiot. 1996,
49, 1014.